Clinical Director

• Jan 2023 - Present

As a clinical director I am responsible to lead a team of healthcare providers toward organization’s goals with the ultimate purpose to provide patients the best clinical care. As a clinical director I am responsible to lead a team of healthcare providers toward organization’s goals with the ultimate purpose to provide patients the best clinical care.

Associate Editor

• Jun 2022 - Present

The Urologic Oncology section of Frontiers in Urology publishes high-quality fundamental clinical and translational research, as well as, in-depth reviews across the field of urologic oncology. This section covers the areas including, but not limited to:- Renal cell carcinoma and other renal pathology- Prostate cancer- Bladder cancer- Testicular cancer- Penile/adrenal tumors- Robotic/laparoscopic/open surgery for urological malignancies- Imaging (including radiology and nuclear medicine) of urological malignancies- Pathological aspect of urological malignanciesAll studies must contribute insights into urologic oncology by highlighting the clinical, surgical, imaging or pathological aspect of this field. Reports dealing with other fields of urology practice do not fall within the scope of this section and should be submitted to other specialized journals.

Guest Editor

• Sep 2021 - Present

Research Topic: Diagnostic and Predictive Biomarkers in Testicular Germ Cell TumorsThe goal of this Research Topic is to provide answers to these clinical questions by use of innovative and advanced methodologies and/or pre-clinical models, validated in clinical samples (tissues and/or liquid biopsies).This Research Topic aims to contribute to the improvement of clinical care of TGCT patients, by discovering novel diagnostic, prognostic and predictive biomarkers of the disease, as well as novel targeted treatments with less toxicity for these young patients.

Urologist

• Mar 2022 - Present

Guest Editor

• Feb 2022 - Present

Research Topic: Tumor microenvironment of urogenital cancers: looking for novel biomarkers and treatments Our understanding of the tumor microenvironment has greatly evolved in recent years and led to important discoveries with implications for patients’ outcome and eligibility for targeted therapies. Urogenital malignancies, including kidney, bladder, prostate, testicular and penile cancers, comprise very diverse and interesting tumor models for investigating several aspects of the tumor microenvironment and its interaction with tumor progression. This includes the study of a wide array of immune cell populations infiltrating the tumor, but also of the interaction with stromal cells, tumor vasculature and extracellular matrix. In this Special Issue we aim to gather original contributions devoted to studying the tumor microenvironment of urogenital malignancies, with the ultimate aim of finding novel biomarkers and therapies with clinical implications for daily practice. In silico and in vitro studies are recommended to include clinical validation in patient samples. Review articles with novel perspectives and establishing the bridge between biology and clinical applications are welcomed.

Guest Editor

• Jan 2022 - Present

Research Topic: Clinical Advances on the Evaluation and Management of Testicular Germ Cell Tumours The goal of this Special Issue is to collate original articles and reviews that explore innovative and advanced methodologies and/or preclinical models, validated in clinical samples (tissues and/or liquid biopsies), and contribute to the improvement of clinical care of TGCT patients by discovering novel diagnostic, prognostic and predictive biomarkers of the disease, as well as novel targeted treatments with less toxicity for these young patients. The specific interests of this Special Issue include: • Pathobiology of TGCTs (genesis and risk factors of TGCTs);TGCTs awareness;Epidemiological trends of TGCTs;Tumor heterogeneity in TGCTs;Histopathological assessment of TGCTs (including molecular pathology and digital pathology contributions); Advances in biomarkers for TGCT patients (including tissue, noninvasive and imaging);Innovative surgical approaches for metastatic TGCTs;Management of stage I TGCT patients;Management of high-risk patients and cisplatin resistant patients;Epigenetic background of TGCTs and epigenetic drugs;Drug discovery/novel targeted treatments for TGCT patients;Long-term treatment side-effects and

Assistant Professor Of Medicine

• Sep 2019 - Present

EAU Guidelines Panel Member

• Jul 2019 - Present

European Association of Urology - Section of Oncological Urology (Associate Member)

• Aug 2019 - Present

EAU Section of Oncological Urology (ESOU)The ESOU covers one of the largest and most diverse subjects in medicine– oncological urology. Our scope embraces all aspects related to causes, detection, prevention, staging, screening, prognosis, non-surgical and surgical treatment of all the common adult urological cancers. We approach this immense field by stimulating scientific research, encouraging continuous education and knowledge-sharing within our subspecialty and across disciplines.

Urology Coordinator

• May 2018 - Present

MD PhD

• Jan 2019 - Present

The role of telomere maintenance in urological malignancies The role of telomere maintenance in urological malignancies